|
Agenus Inc (NASDAQ: AGEN) |
|
Agenus Inc
AGEN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Agenus Inc's sales fell
by -7.06 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1501
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.11 %
Agenus Inc net loss decreased from $-73 millions, to $-55 millions in II. Quarter 2024,
• More on AGEN's Growth
|
|
Agenus Inc realized a net loss in trailing twelve months.
Agenus Inc realized cash reduction of $ -2.3 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.51.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.98.
• More on AGEN's Valuation
|
|
|
|
|
Agenus Inc realized net loss in trailing twelve months.
Agenus Inc realized cash outflow of $ -2.3per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.51.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.98.
• More on AGEN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com